Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis

Table 1 Characteristics of included trials

Ref.	DAA type	Patient type	IL-28B SNP (n)	DAA SVR (n)		DAANon SVR (n)		SOCSVR (n)		SOCNon SVR (n)
				CC	Non CC	CC	Non CC	CC	Non CC	CC	Non CC
Akuta et al[25]	TVR	Mixed	68	31	10	6	21
Bronowicki et al[23]	TVR	Naïve	141	30	30	2	48	7	6	4	14
Flamm et al[26]	BOC	Experienced	146	12	52	7	24	5	6	5	35
Fried et al[22]	SMP	Naïve	153	34	56	1	16	12	17	0	17
Jacobson et al[27]	TVR	Naïve	454	84	127	11	71	35	25	20	81
Lawitz et al[20]	VNP	Experienced	131	14	67	9	16	1	3	2	19
Manns et al[13]	VNP	Naïve	65	22	14	3	10	4	6	1	5
Pol et al[28]	TVR	Experienced	527	60	209	16	137	5	13	12	75
Sulkowski et al[24]	FLP	Naïve	110	22	34	0	14	9	12	2	17
Poordad et al[21]	BOC	Naïve	653	107	198	25	106	50	43	14	110
		Experienced	259	39	105	11	52	6	10	7	29

DAA: Direct acting agents; TVR: Telaprevir; BOC: Boceprevir; SMP: Simeprevir; VNP: Vaniprevir; FLP: Faldaprevir; CC or non CC: Genotype of IL-28B.